NCT00371345

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer

Conditions

• Breast Cancer
• Metastasis

Interventions

Type	Name	Description
DRUG	Dasatinib	Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
DRUG	Dasatinib 100 mg	Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)

Timeline

• Start date: 2006-12-01
• Primary completion: 2009-03-01
• Completion: 2009-05-01
• First posted: 2006-09-04
• Last updated: 2011-04-26
• Results posted: 2010-11-05

Locations

23 sites across 7 countries: United States, Argentina, Belgium, France, Italy, Peru, Spain